(Q37972127)

26 August 2017

title

Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension (English)

1 reference

26 August 2017

main subject

arterial hypertension

0 references

1 reference

0 references

1

Jürgen Venitz

1 reference

26 August 2017

Julia Zack

2

1 reference

26 August 2017

Hunter Gillies

3

1 reference

26 August 2017

Martine Allard

4

1 reference

26 August 2017

Jean Regnault

5

1 reference

26 August 2017

Christopher Dufton

6

1 reference

26 August 2017

publication date

28 December 2011

1 reference

The Journal of Clinical Pharmacology

26 August 2017

published in

1 reference

26 August 2017

volume

52

1 reference

26 August 2017

issue

12

1 reference

26 August 2017

page(s)

1784-1805

1 reference

Development and pathology of pulmonary hypertension.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Diagnosis and assessment of pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Updated clinical classification of pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

The endothelin system in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Effect of steady-state ambrisentan on the pharmacokinetics of a single dose of the oral contraceptive norethindrone (norethisterone) 1 mg/ethinylestradiol 35 microg in healthy subjects: an open-label, single-sequence, single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Potential for pharmacokinetic interactions between ambrisentan and cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Survival with first-line bosentan in patients with primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011423662

21 January 2018

Identifiers

DOI

10.1177/0091270011423662

1 reference

26 August 2017

1 reference